<DOC>
	<DOCNO>NCT01618656</DOCNO>
	<brief_summary>Cannabis dependence associate change brain 's cannabinoid system . When cannabis dependent individual try quit use cannabis , experience problem make difficult achieve maintain abstinence . Therefore , reduce problem related quit cannabis may facilitate abstinence . One way harness brain 's capacity make cannabis-like substance - endocannabinoids . One main endocannabinoids anandamide . The study base hypothesis problem related quit cannabis use reduce increase brain level anandamide . Furthermore , reduce problem related quit cannabis , people less likely relapse . Brain anandamide level increase block breakdown anandamide use fatty acid amide hydrolase inhibitor ( FAAH-I ) . The effect novel FAAH-I cannabis withdrawal relapse cannabis dependent subject study double-blind , randomize , control , proof-of-concept study . Cannabis-dependent subject receive placebo FAAH-inhibitor PF-04457845 2:1 randomization . The trial consist 1 week inpatient stay achieve abstinence , 3 week outpatient treatment phase 8 week follow-up phase . Abstinence relapse measure various time 12 week study .</brief_summary>
	<brief_title>Safety Efficacy FAAH-Inhibitor Treat Cannabis Withdrawal</brief_title>
	<detailed_description />
	<mesh_term>Marijuana Abuse</mesh_term>
	<criteria>1 . Male 2 . Ages 1855 ( inclusive ) 3 . Cannabis Dependence 1 . Allergies intolerance FAAHInhibitors 2 . Current significant medical comorbidities</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>